⏳ Final hours! Save up to 60% OFF InvestingProCLAIM SALE

Cosmos Health expands portfolio with generic drug portfolio acquisition

EditorRachael Rajan
Published 19/01/2024, 01:34 am
© Reuters.
COSM
-

CHICAGO - Cosmos Health Inc. (NASDAQ:COSM), a global healthcare company, announced today the completion of a significant acquisition, purchasing licenses and rights to a portfolio of 10 generic drugs for approximately $3.5 million. This move aims to bolster Cosmos Health's pharmaceutical offerings with treatments targeting diabetes, cholesterol, respiratory, and cardiac conditions.

The acquired portfolio includes drugs such as ASTO-CHOL (Pravastatin) for cholesterol, Diorium (Omeprazole) for stomach issues, and HEART-FREE (Clopidogrel) for heart-related problems, among others. All medicines will be produced by Cana Laboratories, a wholly-owned subsidiary of Cosmos Health.

The acquisition, which was initially disclosed on December 20, 2023, is seen as a strategic step for Cosmos Health to expand its global market presence and diversify its revenue streams. The company's CEO, Greg Siokas, expressed enthusiasm about the acquisition's potential to capture a more substantial share of the global generic drug market, which Vantage Market Research valued at $411.99 billion in 2022 and projected to reach $613.34 billion by 2030.

Cosmos Health, established in 2009, has a diverse healthcare portfolio that includes proprietary pharmaceutical and nutraceutical brands. It also operates a telehealth platform through Texas-based ZipDoctor, Inc. The company has manufacturing facilities in the European Union and distribution centers across Europe and North America.

The global healthcare group is a vertically integrated entity, with capabilities ranging from drug development to marketing and sales. This acquisition is aligned with its goal to transition into a comprehensive pharmaceutical company.

This announcement is based on a press release statement.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.